iBio to Participate in the 33rd Annual Roth Conference
iBio will participate in the 33rd Annual Roth Conference held virtually from March 15-17, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iBio will participate in the 33rd Annual Roth Conference held virtually from March 15-17, 2021. A pre-recorded presentation will be accessible on demand for all registered attendees. Starting March 15, the presentation will also be available on iBio's website under 'News & Events' in the Investors section. iBio is known for its FastPharming® System, which integrates advanced farming and glycosylation technologies to produce monoclonal antibodies, vaccines, and more. The company focuses on biopharmaceutical development targeting fibrotic and infectious diseases.
Details
News Market Reaction – IBIO
The recorded move for IBIO in the trading session of this news was +2.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRYAN, Texas, March 09, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced that it will participate in the 33rd Annual Roth Conference, which will be held virtually from March 15-17, 2021.
iBio's pre-recorded presentation will be available on demand during the virtual event for all registered attendees. Beginning on Monday, March 15, 2021, the presentation will also be available on the Company's website at www.ibioinc.com under "News & Events" in the Investors section.
About iBio, Inc.
iBio is a global leader in plant-based biologics manufacturing. Its FastPharming® System combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks and other proteins. iBio is developing proprietary products on the FastPharming Platform, which include biopharmaceuticals for the treatment of fibrotic and infectious diseases, amongst others. The Company’s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services, including Glycaneering™ Development Services for advanced recombinant protein design. For more information, visit www.ibioinc.com.
Contact:
Stephen Kilmer
iBio, Inc.
Investor Relations
(646) 274-3580
skilmer@ibioinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.